Home >> Signaling Pathways >> Ubiquitination/ Proteasome >> Aclacinomycin A
Related Products
Aclacinomycin A Topoisomerase I and II inhibitor

Catalog No.A2601
Size Price Stock Qty
5mg
$120.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

      

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & MSDS

View current batch:

Chemical structure

Aclacinomycin A

Biological Activity

Description Aclarubicin (aclacinomycin A), an anthracycline drug, specific inhibitor of the 20S proteasome chymotrypsin-like activity.
Targets 20S proteasome          
IC50            

Aclacinomycin A Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Aclacinomycin A Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties

Cas No. 57576-44-0 SDF Download SDF
Synonyms Jaclacin,Aclarubicin,Aclarubicin A
Canonical SMILES OC1=CC=CC(C(C2=C3C(O)=C4C([[email protected]@H](C(OC)=O)[[email protected]@](O)(CC)C[[email protected]@H]4O[[email protected]]5C[[email protected]](N(C)C)[[email protected]](O[[email protected]@H]6O[[email protected]@H](C)[[email protected]@H](O[[email protected]@H]7O[[email protected]@H](C)C(CC7)=O)[[email protected]@H](O)C6)[[email protected]](C)O5)=C2)=O)=C1C3=O
Formula C42H53NO15 M.Wt 811.87
Solubility Soluble in DMSO Storage Store at -20°C
Shipping Condition Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

Background

Aclacinomycin A is a dual inhibitor of topoisomerase I and II [1]. Aclacinomycin A is an anticancer drug which can reduce the tumor with minimal damage to normal cells. Aclacinomycin A shows potency against a wide variety of solid tumours and haematological malignancies. In A549, HepG2 and MCF-7 cells, Aclacinomycin A shows cytotoxic activity with IC50 values of 0.27μM, 0.32μM and 0.62μM, respectively. Aclacinomycin A induces cell apoptosis in these cells and the effects change to be necrosis when the incubation time is prolonged. Aclacinomycin A is demonstrated to increase the activity of both caspase-3 and caspase-8, thus inducing the activation of PARP. Apart from that, as an inhibitor of opoisomerases, Aclacinomycin A is found to induce DNA damage in V79 and irs-2 cells. Aclacinomycin A is used to treat acute leukaemias, lymphomas and other solid tumors through its inhibition of topo II [1, 2].

References:
[1] Hajji N, Mateos S, Pastor N, Domínguez I, Cortés F.  Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor. Mutat Res. 2005 May 2;583(1):26-35.[2] Rogalska A, Szwed M, Jó wiak Z. Aclarubicin-induced apoptosis and necrosis in cells derived from human solid tumours. Mutat Res. 2010 Jul 19;700(1-2):1-10.